These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 4075595)

  • 1. Improvement of anemia with deferoxamine in hemodialysis patients with aluminum-induced bone disease.
    Tielemans C; Collart F; Wens R; Smeyers-Verbeeke J; van Hooff I; Dratwa M; Verbeelen D
    Clin Nephrol; 1985 Nov; 24(5):237-41. PubMed ID: 4075595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of anaemia with desferrioxamine in haemodialysis patients.
    Praga M; Andrés A; de la Serna J; Ruilope LM; Nieto J; Estenoz J; Millet VG; Arnaiz F; Rodicio JL
    Nephrol Dial Transplant; 1987; 2(4):243-7. PubMed ID: 3118265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aluminum intoxication in a child: treatment with intraperitoneal desferrioxamine.
    Warady BA; Ford DM; Gaston CE; Sedman AB; Huffer WE; Lum GM
    Pediatrics; 1986 Oct; 78(4):651-5. PubMed ID: 3763276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 7. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies.
    Touam M; Martinez F; Lacour B; Bourdon R; Zingraff J; Di Giulio S; Drüeke T
    Clin Nephrol; 1983 Jun; 19(6):295-8. PubMed ID: 6872366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypercalcaemic osteomalacia and encephalopathy due to aluminium intoxication in haemodialysis patients. Clinical aspects and treatment with desferrioxamine.
    Mudde AH; Roodvoets AP; Van Groningen K
    Neth J Med; 1985; 28(1):6-11. PubMed ID: 3974771
    [No Abstract]   [Full Text] [Related]  

  • 10. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 11. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 12. Aluminum bone disease. (A case study).
    Coleman S
    J Nephrol Nurs; 1985; 2(3):125-6. PubMed ID: 3848476
    [No Abstract]   [Full Text] [Related]  

  • 13. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition and management of aluminum intoxication in children.
    Tsuru N; Williams JL; Chan JC
    Int J Pediatr Nephrol; 1987; 8(3):177-86. PubMed ID: 3323095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Aluminum-induced osteomalacia in chronic hemodialysis].
    Smetana S; Popovtzer MM; Bar-Khayim Y
    Harefuah; 1987 Jun; 112(12):595-7. PubMed ID: 3428727
    [No Abstract]   [Full Text] [Related]  

  • 17. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone mineral content and treatment with deferoxamine in patients under chronic hemodialysis].
    Zanchetta JR; Bogado CE; Zuchini A; Firmat J
    Medicina (B Aires); 1992; 52(2):184-5. PubMed ID: 1308914
    [No Abstract]   [Full Text] [Related]  

  • 20. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis.
    Faugere MC; Arnala IO; Ritz E; Malluche HH
    J Lab Clin Med; 1986 Jun; 107(6):481-7. PubMed ID: 3486929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.